51. Longitudinal changes in prospective memory and their clinical correlates at 1-year follow-up in first-episode schizophrenia
- Author
-
Yan Zhou, Yu-Tao Xiang, Liang Zhang, Chee H. Ng, Fu-Chun Zhou, David W. K. Man, Gabor S. Ungvari, Jingjing Zhou, Chuanyue Wang, Jun Li, David Shum, and Deng Tang Liu
- Subjects
Male ,Social Sciences ,lcsh:Medicine ,Neuropsychological Tests ,Severity of Illness Index ,0302 clinical medicine ,Cognition ,Learning and Memory ,Sociology ,Prospective memory ,Medicine and Health Sciences ,Medicine ,Antipsychotics ,Psychology ,Longitudinal Studies ,Prospective Studies ,Prospective cohort study ,lcsh:Science ,Cognitive Impairment ,Multidisciplinary ,Cognitive Neurology ,Remission Induction ,Drugs ,Middle Aged ,Phenotype ,Neurology ,Schizophrenia ,Research Design ,Female ,Analysis of variance ,Research Article ,Adult ,medicine.medical_specialty ,China ,Adolescent ,Patients ,Memory, Episodic ,Cognitive Neuroscience ,Research and Analysis Methods ,Education ,03 medical and health sciences ,Young Adult ,Memory ,Internal medicine ,Severity of illness ,Mental Health and Psychiatry ,Humans ,Learning ,Educational Attainment ,Pharmacology ,Analysis of Variance ,Memory Disorders ,business.industry ,lcsh:R ,Cognitive Psychology ,Repeated measures design ,Biology and Life Sciences ,medicine.disease ,030227 psychiatry ,Health Care ,Social Class ,Endophenotype ,Case-Control Studies ,Cognitive Science ,lcsh:Q ,business ,Neurocognitive ,030217 neurology & neurosurgery ,Follow-Up Studies ,Neuroscience - Abstract
This study aimed to investigate prospective memory (PM) and the association with clinical factors at 1-year follow-up in first-episode schizophrenia (FES). Thirty-two FES patients recruited from a university-affiliated psychiatric hospital in Beijing and 17 healthy community controls (HCs) were included. Time- and event-based PM (TBPM and EBPM) performances were measured with the Chinese version of the Cambridge Prospective Memory Test (C-CAMPROMPT) at baseline and at one-year follow-up. A number of other neurocognitive tests were also administered. Remission was determined at the endpoint according to the PANSS score ≤ 3 for selected items. Repeated measures analysis of variance revealed a significant interaction between time (baseline vs. endpoint) and group (FES vs. HCs) for EBPM (F(1, 44) = 8.8, p = 0.005) and for all neurocognitive components. Paired samples t-tests showed significant improvement in EBPM in FES (13.1±3.7 vs. 10.3±4.8; t = 3.065, p = 0.004), compared to HCs (15.7±3.6 vs. 16.5±2.3; t = -1.248, p = 0.230). A remission rate of 59.4% was found in the FES group. Analysis of covariance revealed that remitters performed significantly better on EBPM (14.9±2.6 vs. 10.4±3.6; F(1, 25) = 12.2, p = 0.002) than non-remitters at study endpoint. The association between EBPM and 12-month clinical improvement in FES suggests that EBPM may be a potential neurocognitive marker for the effectiveness of standard pharmacotherapy. Furthermore, the findings also imply that PM may not be strictly a trait-related endophenotype as indicated in previous studies.
- Published
- 2017